Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

PD
Remote Monitoring of Automated Peritoneal Dialysis Improves Personalization of Dialytic Prescription and Patient’s Independence. - Milan Manani et al.
Visit resource site
PD
Remote Patient Management in Automated Peritoneal Dialysis: A Promising New Tool - Drepper V.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Removal evaluation of a new dialyzers with medium cut-off membrane in HD treatments
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Removal of Middle Molecules Using Medium Cut-Off Membranes in Hemodialysis Mode vs. High-Flux Membranes in Post-Dilutional Online Hemodiafiltration Mode: The REMOC Study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Removal of middle molecules with medium cutoff dialyzer in patients on short frequent hemodialysis
Visit resource site
HD
Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility - Grundström G, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Reply to “Comparison of four medium cut-off dialyzers”
Visit resource site
HD
Requirements and Pitfalls of Dialyzer Sieving Coefficients Comparisons - Hulko et al.
Visit resource site
HD
Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis - Laville et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Retention of beneficial molecules and coagulation factors during haemodialysis and haemodiafiltration
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Rhabdomyolysis-Induced Acute Kidney Injury Treated with Medium Cut-Off Membrane: A Case Report.
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.